Minimally invasive radioguided parathyroidectomy.

Area of Science:

• Endocrine Surgery
• Nuclear Medicine
• Surgical Oncology

Background:

• Primary hyperparathyroidism often requires surgical intervention.
• Minimally invasive radioguided parathyroidectomy (MIRP) is an advanced surgical approach.
• MIRP integrates technetium sestamibi scans, gamma probe, methylene blue dye, and parathyroid hormone (PTH) monitoring.

Purpose of the Study:

• To evaluate the safety and efficacy of MIRP for primary hyperparathyroidism.
• To assess the effectiveness of MIRP in correcting hypercalcemia.
• To determine the feasibility of MIRP as an outpatient procedure.

Main Methods:

• Patients with primary hyperparathyroidism underwent preoperative technetium sestamibi scans.
• Intraoperative administration of technetium sestamibi and methylene blue dye.
• Gamma probe-guided dissection and intraoperative PTH level monitoring.
• Excision of abnormal parathyroid glands guided by imaging and PTH levels.

Main Results:

• Hypercalcemia was corrected in all 39 patients (36 primary, 3 recurrent hyperparathyroidism).
• High success rate in identifying single adenomas (32/36) and abnormal glands.
• Minor complications in 8% of patients; 44% discharged same day, 83% within 23 hours.
• MIRP demonstrated lower costs compared to standard exploration due to reduced operative time, anesthesia, and hospital stay.

Conclusions:

• MIRP is a safe and effective treatment for primary hyperparathyroidism, achieving complete hypercalcemia correction.
• The combination of gamma probe and methylene blue dye enables precise gland localization and minimal dissection.
• Intraoperative PTH assay confirms successful gland removal, supporting outpatient management.
• MIRP offers benefits of a small incision, rapid recovery, and high patient satisfaction.